XOMA Royalty (XOMA) Non-Current Deferred Tax Liability (2025 - 2026)
XOMA Royalty's (XOMA) quarterly Non-Current Deferred Tax Liability came in at $103000.0 in Q1 2026, little changed quarter-over-quarter from $103000.0 in Q4 2025.
XOMA Royalty (XOMA) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non-Current Deferred Tax Liability across 2 years of filings, most recently posting $103000.0 for Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $103000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $103000.0 (changed N/A YoY), and the FY2025 annual result was $103000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $103000.0 for Q1 2026 at XOMA Royalty, roughly flat from $103000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $103000.0 in Q4 2025 to a low of $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103,000.00 |
| Mar 31, 2026 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |